Compare Boston Scientific Corporation (BSX) vs Celsius Holdings, Inc. (CELH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Celsius Holdings, Inc. — how do they compare? Boston Scientific Corporation trades at $51.12 (market cap $71.46B), while Celsius Holdings, Inc. trades at $28.03 (market cap $6.89B). The key difference: Boston Scientific Corporation is far larger — about 10.4× Celsius Holdings, Inc.'s market cap. Which is the better fit depends on your goals.
| BSX | CELH | |
|---|---|---|
Market Cap | $71.46B | $6.89B |
Sector | Health | Consumer Staples |
52-Week High | $108.14 | $64.86 |
52-Week Low | $42.63 | $23.77 |
Enterprise Value | $83.55B | $8.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.
BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.
CELH trades at $27.77, up 16.83% in 24 hours, but technical indicators signal a bearish trend. The company reported Q2 2026 earnings of $0.36 per share, missing estimates, with revenue growth slowing to 11% year-over-year. Recent news includes an analyst downgrade and leadership changes amid an organizational realignment. Valuation metrics remain elevated with a P/E of 120.74 and P/S of 2.37.
The outlook is mixed: strong analyst consensus (95.65% buy ratings) and a $44.08 price target suggest upside, but risks include core brand weakness, margin pressure, and a pending legal investigation. Investors should weigh growth potential from Alani Nu and Rockstar integrations against execution challenges and high valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →
